Trial intelligence / Profile preview

Asciminib versus investigator-selected tyrosine kinase inhibitor in newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

2021-000678-27Phase 3Active

Sponsor

Novartis

Start

Jun 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1